Ceprate SC stem cell concentration system data

CPRO announced Phase III findings with the Ceprate system in 134 patients who were eligible for a peripheral blood stem cell transplant, showing a 3.3 log mean reduction in myeloma cells contaminating the transplant. The open-label trial was presented at the International Workshop

Read the full 438 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE